Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China.
The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen 518020, China.
Biomed Res Int. 2022 Aug 31;2022:9545609. doi: 10.1155/2022/9545609. eCollection 2022.
ALDH+ H1975 lung adenocarcinoma stem cells (LSCs) are a rare cell population identified in lung adenocarcinoma (LUAD). LSCs can self-renew, drive tumor initiation, growth, metastasis, and recurrence and are also the predominant cause of poor prognosis due to their intrinsic resistance to drugs and chemotherapy. Consequently, LSCs are a promising target for LUAD therapy. Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), exert many significant regulatory functions in the pathogenesis of human cancers, showing the necessity for a comprehensive understanding of the mechanisms that underlie lung carcinogenesis. Nonetheless, research on many known transcripts and messenger RNAs (mRNAs) has already generated new information. Unknown biomarkers in ncRNAs and systematic and comprehensive interrelation with unknown ncRNAs and mRNAs may provide further insights into the biology of LUAD. Herein, a set of novel ncRNAs that include miRNAs, lncRNAs, and circRNAs were identified, and differentially expressed patterns of ncRNAs and mRNAs in LSCs and ALDH-H1975 LUAD tumor cells (LTCs) were obtained using stringent bioinformatics pipelines. Through a meta-analysis of the identified landscapes, novel competitive endogenous RNA (ceRNA) networks were constructed to reveal the potential molecular mechanisms that regulate the hallmarks of LSCs and LTCs. This study presents a summary of novel ncRNAs and the fundamental roles of differentially expressed ncRNAs implicated in the activity of LSCs and LTCs. In addition, the study also provides a comprehensive resource for the future identification of diagnostic, therapeutic, and prognostic biomarkers in LUAD.
ALDH+ H1975 肺腺癌干细胞(LSCs)是在肺腺癌(LUAD)中鉴定的一种罕见细胞群体。LSCs 可以自我更新,驱动肿瘤起始、生长、转移和复发,并且由于其对药物和化疗的内在耐药性,也是导致预后不良的主要原因。因此,LSCs 是 LUAD 治疗的一个有前途的靶点。非编码 RNA(ncRNA),包括 microRNAs(miRNAs)、长非编码 RNA(lncRNA)和环状 RNA(circRNA),在人类癌症的发病机制中发挥着许多重要的调节功能,这表明有必要全面了解导致肺癌发生的机制。尽管如此,对许多已知转录本和信使 RNA(mRNA)的研究已经产生了新的信息。ncRNA 中的未知生物标志物以及与未知 ncRNA 和 mRNA 的系统和全面相互关系可能会进一步深入了解 LUAD 的生物学特性。在此,通过严格的生物信息学管道,鉴定了一组包括 miRNAs、lncRNAs 和 circRNAs 在内的新型 ncRNA,并获得了 LSCs 和 ALDH-H1975 LUAD 肿瘤细胞(LTCs)中 ncRNA 和 mRNA 的差异表达模式。通过对鉴定的图谱进行荟萃分析,构建了新的竞争性内源 RNA(ceRNA)网络,以揭示调节 LSCs 和 LTCs 特征的潜在分子机制。本研究总结了新型 ncRNA 以及差异表达的 ncRNA 在 LSCs 和 LTCs 活性中所涉及的基本作用。此外,该研究还为未来在 LUAD 中识别诊断、治疗和预后生物标志物提供了全面的资源。